Clinical Trial Update: A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A Phase 4, 12-week study comparing umeclidinium 62.5 mcg with glycopyrronium 44 mcg in chronic obstructive pulmonary disease to evaluate efficacy and safety; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrronium (glycopyrrolate) - Seebri Neohaler (glycopyrronium)
• Umeclidinium (Incruse Ellipta) (umeclidinium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2016-02-15